ImmuSmol team combines 25 years of experience in the design and development of small molecule antibodies. Our R&D activities also involve a worldwide network of scientific consultants and collaborators, bringing expertise in areas such as chemistry, immunology, oncology and neuroscience.
|Alban Bessede, PhD|
|Founder, Chief Executive Officer|
Born and bred in Bordeaux, Alban founded ImmuSmol immediately after a post-doc in Sydney. Trained in immunology, he gained expertise in small molecule antibodies in the course of his research in oncology and neurodegeneration, eventually leading him to envisage their use in diagnostics and therapy.
|Dominique Bodet, PhD|
Over his career, Dominique developed over 70 small molecule antibodies. Initially trained in biochemistry and immunology, he has overseen all ImmuSmol lab operations, from antigen design up to in vivo studies, since the inception of the company in 2012.
Board of directors
|Vincent Picq, MSc|
|Founder, Chairman of Schiever|
Vincent Picq has been supporting ImmuSmol since the very beginning. Head of a retailing group with annual sales exceeding €1,3 billion, he is providing ImmuSmol with strategic, management and administrative support.
Scientific consultants & collaborators
- Tumour metabolism
Eyal Gottlieb, PhD
Beatson Insitute for Cancer Research (UK) - More...
- Tryptophan metabolism in neuroinflammation
Gilles Guillemenin, PhD
Macquarie University (Australia) - More...
- Tryptophan metabolism
Francesca Fallarino, PhD
University of Perugia (Italy) - More...
- Metabolic disorders
Odile Poulain-Goddefroy, PhD
Institut Pasteur de Lille (France) - More...
Marc Veldhoen, PhD
Babraham Institute (UK) - More...